Sankala Group
PTGX icon

Sankala Group’s Protagonist Therapeutics PTGX Stock Holding History

Sankala Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.5K Hold
60
– – 0.01% 405
2026
Q2 		$9.47K Hold
60
– – 0.01% 404
2026
Q1 		$6.07K Hold
60
– – 0.01% 425
2025
Q4 		$5.52K Buy
+60
New +$4.91K ﹤0.01% 446

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Sankala Group's PTGX Position: Q3 2026 in Review

Sankala Group held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 60 shares worth $8.5K. The position accounts for 0.01% of the portfolio, ranked #405.

Sankala Group first reported a position in PTGX in Q4 2025 and has held it in 4 quarters since. The position peaked at $9.47K in Q2 2026. 190 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Sankala Group held 60 shares of Protagonist Therapeutics worth $8.5K as of Q3 2026.
  • Sankala Group left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up 0.01% of Sankala Group's portfolio in Q3 2026, its #405 holding.
  • Sankala Group first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Protagonist Therapeutics position peaked at $9.47K in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.